Most Read Articles
3 days ago
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Pearl Toh, 2 days ago
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.

SGLT2 inhibitors may decrease heart failure risk

Audrey Abella
25 Jul 2017

The use of sodium-glucose co-transporter 2 (SGLT2) inhibitors such as empagliflozin and canagliflozin may lead to a decreased risk of heart failure (HF), according to data presented at the Asian Pacific Society of Cardiology Congress (APSC) 2017 held in Singapore.

“Empagliflozin, canagliflozin, and maybe metformin, are … beneficial [in reducing HF risk],” said Dr Darren McGuire from the University of Texas Southwestern Medical Center in Dallas, Texas, US, who highlighted the decreased HF risk with antihyperglycaemic agents as shown in the EMPA-REG OUTCOME* and CVD-REAL** trials.

In the EMPA-REG OUTCOME trial, 7,020 patients with prevalent atherosclerotic vascular disease and type 2 diabetes were randomized to receive placebo (n=2,333), empagliflozin 10 mg once daily (n=2,345), or empagliflozin 25 mg once daily (n=2,342). [N Engl J Med 2015;373:2117-2128; Cardiovasc Diabetol 2014;13:102]

The lower risk of HF among patients on empagliflozin was observed within the first 6–9 months of the trial (hazard ratio [HR], 0.65, 95 percent confidence interval [CI], 0.50–0.85; p=0.0017).

“[This] continued to divert slightly throughout the follow-up period … leading to the 35 percent relative risk reduction in incident [HF],” said McGuire, who suggested an increase in haematocrit (4 percent) as a potential reason for the reduction in HF. “This was a stunning finding … [W]e were very interested [to determine if] this was unique to empagliflozin or [if it was] a class effect.”

In the CVD-REAL trial, 154,528 participants receiving an SGLT2 inhibitor were matched with 154,528 individuals receiving other glucose-lowering drugs. [Circulation 2017;136:249-259]

Overall results revealed a decreased risk of hospitalization for HF with SGLT2 inhibitors (HR, 0.61, 95 percent CI, 0.51–0.73; p<0.001), which is also suggestive of a class effect, noted McGuire.

Given the favourable cardiovascular outcomes resulting from SGLT2 antagonist use, the European Society of Cardiology (ESC) HF prevention guidelines encourage the use of this class of glucose-control drugs, specifically empagliflozin, for cardiovascular death and HF risk reduction, noted McGuire.

McGuire pointed out that the benefits of metformin in this aspect warrants further investigation. “[There is] emerging data suggesting metformin may be in fact beneficial … [however], to this day, we have no idea what the cardiovascular safety or efficacy of metformin is, specifically [in relation] to HF.”

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Pearl Toh, 2 days ago
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.